In the realm of scientific collaboration, the Karolinska Institutet Research Incubator (KIRI) stands as a beacon of innovation, fostering interdisciplinary partnerships that push the boundaries of research. This article delves into the story of Drs. Hanna Brauner and Nikolas Herold, two clinical researchers who, through KIRI, embarked on a journey to improve the treatment of skin lymphoma. Their collaboration, marked by equality and open discussion, showcases the transformative power of diverse expertise and a supportive research environment.
A Natural Partnership
Dr. Brauner, a dermatologist with a keen interest in cancer biology, and Dr. Herold, a paediatric oncologist, found common ground at KIRI. Their shared passion for understanding cancer's intricacies led them to collaborate on a project that could potentially revolutionize skin lymphoma treatment. Dr. Brauner's expertise in skin inflammation and natural killer (NK) cells, combined with Dr. Herold's insights into immunological processes in tumours, created a powerful synergy.
"I wanted to step out of my comfort zone and explore new connections," Dr. Brauner shared. "KIRI provided an opportunity to engage with different ideas and expertise, fostering an environment conducive to innovation."
Unlocking the Power of Collaboration
The collaboration between these two experts was not just a coincidence; it was a deliberate choice. Dr. Herold emphasized the importance of diverse expertise in complex projects, stating, "Complex projects require a range of expertise, and besides, it's much more enjoyable working that way."
Their project focused on the enzyme SAMHD1 and its impact on immune cells in skin lymphoma. Dr. Herold's decade-long research on the enzyme revealed its changing expression during the disease's aggressive phase. This discovery led to two significant findings with potential therapeutic implications.
New Therapies on the Horizon
First, the immunological line of inquiry revealed that NK cells, typically effective in repelling lymphoma, were down-regulated at the disease site. Dr. Brauner explained, "A possible treatment would be to activate them locally."
Second, cell cultures demonstrated that combinations of existing drugs could bypass the drug-suppressive effect of SAMHD1, making skin lymphoma more receptive to other medications. Dr. Herold exclaimed, "We found that, 'Wow, this drug makes SAMHD1 disappear!', which in turn makes the skin lymphoma more receptive to other medication."
The Power of Serendipity in Research
What makes this collaboration truly remarkable is the serendipitous nature of its findings. Dr. Brauner and Dr. Herold admitted that these results were not part of their initial project plan. "Which is why they weren't in the project plan, but that's the exciting thing about research - getting findings you hadn't been counting on," Dr. Herold noted.
"Often, the results take you forward. You have to be prepared to re-evaluate what's most important and how everything's connected," Dr. Brauner added.
Navigating the Research Landscape
Collaborating as researchers with different backgrounds presented unique challenges. Dr. Brauner and Dr. Herold had to be creative in their meeting solutions, often engaging in productive lunchtime discussions. Dr. Brauner advised, "Make sure early on that entire research groups are able to meet up. We had lunch together and it was really great, with lots of discussions on the margins of the project."
Despite their different approaches, the collaboration proved highly productive. Dr. Herold attributed this to their complementary strengths: "Hanna's wise and thinks things through, whereas I can be very impulsive. It's a combination that has proved very productive."
The Value of Equality and Open Discussion
One of the key strengths of their collaboration was the equality of shared leadership. Dr. Herold emphasized, "Neither of us is in charge or is a junior partner, which better reflects how things are outside academia. You have to argue your point, which means that the best ideas have the greatest chance of winning."
Dr. Brauner echoed this sentiment, "We've had a frank and sincere discussion climate. We're super-experts in our respective fields and rather naïve about each other's, so we've questioned each other: 'What are you thinking? Why is that the obvious next step?' It's been highly instructive."
Socializing and Networking
Beyond the scientific collaboration, KIRI's social environment played a crucial role in fostering connections. Dr. Herold highlighted the value of informal gatherings, "One shouldn't underestimate the value of meeting at the faculty club over a pizza and a glass of wine. It creates an environment that's conducive to conversation, be it on the difficulties of getting grants and private matters or about our research."
Dr. Brauner also emphasized the added value of KIRI, stating, "KIRI isn't only about the postdoc project, even if it is a good initiative that makes people work a little harder on networking. It needs stating that there's other added value in coming together as different research fields and departments."
A Model for Interdisciplinary Collaboration
The success of Dr. Brauner and Dr. Herold's collaboration serves as a model for interdisciplinary research. KIRI, with its focus on young researchers and its platform for fostering partnerships, has become a catalyst for groundbreaking discoveries. As KIRI continues to grow, it will undoubtedly inspire more innovative collaborations, pushing the boundaries of scientific knowledge and ultimately improving patient care.
